Celerion recognised as industry leader in CRO awards for third year running

Celerion has announced it has been recognised as an industry leader in multiple categories of Life Science Leader's annual CRO Leadership Awards for 2018 for the third consecutive year.

The company as recognised as a contract research organisation (CRO) leader in five categories — capabilities, compatibility, expertise, quality and reliability — in all three groups of respondents — big pharma, small pharma and overall (combined big and small).

"We recognise that our clients are faced with increasing complexities and challenges in drug development as well as choices in development partners," said Susan Thornton, president and CEO. "We thank them for this recognition and for their continued trust in our dedication to providing them with high-quality work. It is through their support that we are able to advance our mission of helping them get their drugs to market faster, so that together, we touch the lives of our family, friends and people in need around the world." 

The CRO Leadership Awards are now in the sixth year and are the result of a collaborative venture by Life Science Leader and Industry Standard Research (ISR). The aim of the awards was to provide Life Science Leader readers with accurate and reliable customer feedback to help them choose a reputable partner for clinical research needs.

Survey participants were recruited from pharma and biopharma companies of all sizes and were screened for decision-making influence related to working with CROs. Respondents are only able to evaluate companies that they have worked with within the past 18 months, which means that the responses are based on actual involvement and experiential data.

More than 70 CROs were assessed on over 20 performance metrics for this year's awards, the complete results of which will be published in the May issue of the Life Science Leader magazine.